FXR polyclonal Antibody | GCP41

FXR polyclonal Antibody | GCP41 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human

Application: WB

Application Range: WB: 1:1000~1:2000

Background: The farnesoid X receptor (FXR/NR1H4) is a member of the nuclear hormone receptor superfamily and is a master regulator of bile acid synthesis. FXR/NR1H4 heterodimerizes with RXR-alpha upon activation by bile acids, which begins a regulatory cascade involving SHP and LRH-1 to control lipid homeostasis. FXR/NR1H4 has also been shown to be a critical regulator of glucose homeostasis. In addition to directly regulating genes, FXR/NR1H4 also plays a post transcriptional role in bile acid metabolism by transcribing the RNA-binding protein ZFP36L1, which in turn downregulates the key enzyme Cyp7a1. Mutations in human FXR/NR1H4 have been shown to cause cholestasis and liver disease in neonatal patients. FXR/NR1H4 can also control Lgr5+ intestinal stem cell proliferation and its upregulation has been shown to inhibit colorectal cancer progression. Agonists against FXR/NR1H4 are being evaluated for various liver diseases and diabetes.

Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: FXR polyclonal Antibody detects endogenous levels of FXR protein.

Molecular Weight: ~ 67 kDa

Note: For research use only, not for use in diagnostic procedure.

Alternative Names: Bile acid receptor; Farnesoid X-activated receptor; Farnesol receptor HRR-1; Nuclear receptor subfamily 1 group H member 4; Retinoid X receptor-interacting protein 14; RXR-interacting protein 14; NR1H4; BAR; FXR; HRR1; RIP14

Immunogen: Synthetic peptide, corresponding to Human FXR.

Conjugate: Unconjugated

Modification: Unmodification

Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Pathway: N/A